Regulus Therapeutics Faces Major Change as Nasdaq Removal Looms - What Investors Should Know

Rhea-AI Filing Summary

Regulus Therapeutics has filed Form 25-NSE, notifying its voluntary delisting from the Nasdaq Stock Market. The filing, dated June 28, 2025, confirms the removal of the company's Common Stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

Key details:

• Filing processed by Nasdaq AVP Tara Petta on June 25, 2025
• Company headquarters: 4224 Campus Point Court, Suite 210, San Diego, CA 92121
• Commission File Number: 001-35670

This delisting action was executed under 17 CFR 240.12d2-2(c), indicating that Regulus has voluntarily chosen to delist and has complied with all Exchange requirements and SEC regulations governing voluntary withdrawal of securities. This action could significantly impact stock trading and investor access to the company's shares in public markets.

Positive

• None.

Negative

• Regulus Therapeutics (RGLS) is being delisted from the Nasdaq Stock Market, indicating severe non-compliance with listing requirements or financial distress
• Delisting will likely result in reduced liquidity and institutional investor access for shareholders
• Moving to over-the-counter markets typically signals increased investment risk and reduced market visibility

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-35670

Issuer:	Regulus Therapeutics Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	4224 Campus Point Court, Suite 210
	San Diego	CALIFORNIA	92121
Telephone number:					858-202-6300

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-06-25	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why is RGLS being delisted from Nasdaq in June 2025?

Regulus Therapeutics Inc. (RGLS) is being removed from listing on the Nasdaq Stock Market LLC. This Form 25 notification was filed on June 28, 2025, initiating the delisting process. The filing indicates the exchange has complied with its rules to strike the class of securities (Common Stock) from listing and/or withdraw registration.

What happens to RGLS stock after the Nasdaq delisting?

After delisting from Nasdaq, RGLS common stock will no longer be traded on the Nasdaq Stock Market. The Form 25 filing serves as an official notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. Investors should note this typically means the stock may trade on over-the-counter (OTC) markets if eligible.

Where is RGLS headquarters located as of the delisting notice?

According to the Form 25 filing, Regulus Therapeutics Inc. is headquartered at 4224 Campus Point Court, Suite 210, San Diego, California 92121. The company's telephone number is listed as 858-202-6300.

When did Nasdaq file the Form 25 for RGLS delisting?

The Form 25 for RGLS delisting was signed by Nasdaq Stock Market LLC's AVP Tara Petta on June 25, 2025, with the official SEC filing date being June 28, 2025.